Rhabdomyosarcoma is a type of cancer that is involved in the soft tissues such as muscles, connective tissue (such as tonsils or cartilage), or bone. Rhabdomyosarcoma usually starts in the muscles attached to the bones and help the body move, but it can affect in many parts of the body. Rhabdomyosarcoma is the most common type of cancer that is generally found in children.
The exact cause of the disease is not known but is more common in male child. In addition, children who have a higher birth weight have a higher risk of developing rhabdomyosarcoma. The most common symptom of rhabdomyosarcoma includes headache, trouble with urination or bowel movement, blood in the urine, bleeding in the throat, nose, vagina, and rectum.
Impact of COVID-19 on Rhabdomyosarcoma Treatment Market
- COVID-19 has created an economic crisis in addition to the healthcare crisis. COVID-19 pandemic has stretched the healthcare system worldwide; developed countries are expected to cause an economic recession. The pandemic has harmed the healthcare system, resulting in a 50% to 70% drop in revenue from the month of March. Many small hospitals, clinics, and nursing homes have been forced to shut their operations. In addition, social distancing and localized curfews have resulted in delayed elective surgical procedures. Further, visa cancellations have led to an interruption in medical tourism and can negatively impact the healthcare services market growth.
- COVID-19 has Impacted the Rhabdomyosarcoma treatment market as more focus is given to the COVID-19 treatment and less focus to other treatments. Many companies are researching on COVID-19, but only a few companies reseraches on rare cancer diseases such as rhabdomyosarcoma.
Top Impacting Factors: Market Scenario Analysis, Trends, Drivers, and Impact Analysis
- The rhabdomyosarcoma treatment market has been growing as more people are facing this disease. The market growth has been declining due to the pandemic. This is mainly because of the more focus on the COVID-19 crisis and less focus on other healthcare sectors. The growing technology, as well as the awareness about the disease as well as the treatment and the risk associated with sarcoma, are key factors for the market growth.
- The factors that drive the rhabdomyosarcoma treatment market includes, the rising demand for better healthcare facilities, huge healthcare investments by the government, the increased risk associated with sarcoma, advancement in technology, increase in the government expenditure on the healthcare system, awareness about rhabdomyosarcoma, and increasing prevalence in most countries also improves market growth.
- The factor that restrains the growth of the market includes high cost of treatment, government regulations as these products need to be approved by the government regulatory body. Another factor that hinders market growth includes the risk associated with the treatment as it requires a professional as well as skilled surgeons for treatment.
- North America dominates the market for the treatment of rhabdomyosarcoma due to the high rate of rhabdomyosarcoma in U.S. alone. The research focused on the disease has increased in the country. Also, Europe is expected to grow at the fastest rate in the estimated period due to patient increment which will lead to future market growth and an increase in research and development spending on the healthcare sector. Asia-Pacific is expected to grow at a rapid pace during the test due to government efforts to improve health facilities. The Middle East and Africa have the least market share in the global rhabdomyosarcoma market. An increase in cases of rhabdomyosarcoma is the factor that drives the market share in this region.
Market Trends:
SHEPHERD Therapeutics has announced its collaboration with Mayo Clinic to advance research in Rhabdomyosarcoma by using SHEPARD’s precision-Oncology Platform which is known as DELVE in February 25, 2021.
Key Benefits of the Report
- This study presents the analytical depiction of the rhabdomyosarcoma treatment industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the rhabdomyosarcoma treatment market share.
- The current market is quantitatively analyzed to highlight the rhabdomyosarcoma treatment market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed rhabdomyosarcoma treatment market analysis based on competitive intensity and how the competition will take shape in the coming years
Questions Answered in the Rhabdomyosarcoma Treatment Report
- Who are the leading players active in the rhabdomyosarcoma treatment market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is "rhabdomyosarcoma treatment"?
- What is "rhabdomyosarcoma treatment" market prediction in the future?
Rhabdomyosarcoma Treatment Market Report Highlights
| Aspects | Details |
 By Disease |
|
 By Diagnostics |
|
 By End User |
|
 By Region |
|
 Key Market Players | Novartis AG, MacroGenics, Inc., Eli Lilly & Company,, SHEPHERD Therapeutics, Inc, TAIHO ONCOLOGY, Inc, Boehringer Ingelheim International GMBH., Exelixis, Inc., CELGENE Corporation (A BRISTOL MYERS SQUIBB COMPANY), Oasmia Pharmaceutical AB., Bellicum Pharmaceuticals, Inc., Eisai Co., Ltd, Mayo Foundation for Medical Education and Research., Pfizer Inc, Bristol Myers Squibb Company, Tarveda Therapeutics |
Loading Table Of Content...
